Preparation and characterization of Duloxetine-loaded nanofiber scaffold composed of polyvinyl alcohol and chitosan as wound healing agent, fabricated by electrospinning method.
{"title":"Preparation and characterization of Duloxetine-loaded nanofiber scaffold composed of polyvinyl alcohol and chitosan as wound healing agent, fabricated by electrospinning method.","authors":"Kimiya Pourdehghan, Faraz Najafi, Fatemeh Majdi, Nooshafarin Amani, Nasrin Samadi, Hamid Akbari Javar","doi":"10.1080/10837450.2025.2486797","DOIUrl":null,"url":null,"abstract":"<p><p>Wound is a disruption in the epithelial integrity of the skin or mucosa, which is caused by internal or external pathological processes. In this study, a nanofiber as wound dressing loaded with Duloxetine was produced by electrospinning technique. The diameter of nanofibers containing 20% and 40% Duloxetine was around 236 nm and 272 nm, respectively. Tensile testing results showed that elongation at break percentage soared from 11.5% for drug-free nanofibers to 40.01% for nanofibers containing 40% Duloxetine. All nanofibers had uniform bead-free structure. Contact angle of nanofibers with and without drug was 84.3° and 99.3°, respectively. The drug release profile revealed that after the burst release over the first 8 hours, the curve witnessed a slow sustained release for a longer period. The nanofibers had antibacterial activity against gram-positive and gram-negative bacteria and the crosslinked nanofibers with 40% duloxetine had the largest diameter of inhibition zone at roughly 43 mm for Staphylococcus aureus, 40 mm for Escherichia coli, and 30 mm for Pseudomonas aeruginosa. Clinical studies showed that the percentage of wound area reduction was approximately 96.41% for nanofibers containing 40% duloxetine which was higher than positive control containing phenytoin at around 92.24% and also the other group with 20% duloxetine at 81.68%.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1-59"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical Development and Technology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10837450.2025.2486797","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Wound is a disruption in the epithelial integrity of the skin or mucosa, which is caused by internal or external pathological processes. In this study, a nanofiber as wound dressing loaded with Duloxetine was produced by electrospinning technique. The diameter of nanofibers containing 20% and 40% Duloxetine was around 236 nm and 272 nm, respectively. Tensile testing results showed that elongation at break percentage soared from 11.5% for drug-free nanofibers to 40.01% for nanofibers containing 40% Duloxetine. All nanofibers had uniform bead-free structure. Contact angle of nanofibers with and without drug was 84.3° and 99.3°, respectively. The drug release profile revealed that after the burst release over the first 8 hours, the curve witnessed a slow sustained release for a longer period. The nanofibers had antibacterial activity against gram-positive and gram-negative bacteria and the crosslinked nanofibers with 40% duloxetine had the largest diameter of inhibition zone at roughly 43 mm for Staphylococcus aureus, 40 mm for Escherichia coli, and 30 mm for Pseudomonas aeruginosa. Clinical studies showed that the percentage of wound area reduction was approximately 96.41% for nanofibers containing 40% duloxetine which was higher than positive control containing phenytoin at around 92.24% and also the other group with 20% duloxetine at 81.68%.
期刊介绍:
Pharmaceutical Development & Technology publishes research on the design, development, manufacture, and evaluation of conventional and novel drug delivery systems, emphasizing practical solutions and applications to theoretical and research-based problems. The journal aims to publish significant, innovative and original research to advance the frontiers of pharmaceutical development and technology.
Through original articles, reviews (where prior discussion with the EIC is encouraged), short reports, book reviews and technical notes, Pharmaceutical Development & Technology covers aspects such as:
-Preformulation and pharmaceutical formulation studies
-Pharmaceutical materials selection and characterization
-Pharmaceutical process development, engineering, scale-up and industrialisation, and process validation
-QbD in the form a risk assessment and DoE driven approaches
-Design of dosage forms and drug delivery systems
-Emerging pharmaceutical formulation and drug delivery technologies with a focus on personalised therapies
-Drug delivery systems research and quality improvement
-Pharmaceutical regulatory affairs
This journal will not consider for publication manuscripts focusing purely on clinical evaluations, botanicals, or animal models.